TMCI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Treace Medical Concepts, Inc (TMCI) does not present a strong buy opportunity for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The stock is currently in a neutral technical position with no clear upward momentum, lacks positive catalysts, and has mixed analyst ratings with lowered price targets. Additionally, the company's financial performance shows declining revenue and gross margin, despite improvements in net income and EPS. Given these factors, it is best to hold off on investing in TMCI at this time.
The MACD histogram is positive but contracting, RSI is neutral at 48.944, and moving averages are converging, indicating no clear trend. Key support and resistance levels are at S1: 1.61 and R1: 2.222, suggesting limited upside potential in the short term.
No recent news or events serve as a positive catalyst. The company's net income and EPS have improved significantly YoY.
No significant hedge fund or insider activity has been observed.
In Q4 2025, revenue declined to $62.52M (-9.01% YoY), gross margin dropped slightly to 80.62% (-0.15% YoY), but net income improved to -$9.39M (+1775.05% YoY), and EPS increased to -0.15 (+1400.00% YoY).
Analysts have mixed views. Lake Street maintains a Buy rating with a reduced price target of $7, citing favorable risk-reward for patient investors. UBS and Truist have lowered their price targets to $2.25 and $2, respectively, with neutral or hold ratings due to concerns about growth and product mix.
